Activin receptor-like kinase5 inhibition suppresses mouse melanoma by ubiquitin degradation of Smad4, thereby derepressing eomesodermin in cytotoxic T lymphocytes.

Activin receptor-like kinase5 inhibition suppresses mouse melanoma by ubiquitin degradation of Smad4, thereby derepressing eomesodermin in cytotoxic T lymphocytes.
复制标题

DOI:
10.1002/emmm.201302524
复制
发表时间:
2013-11
影响因子:
11.1
通讯作者:
Mamura, Mizuko
Mamura, Mizuko
中科院分区:
医学1区
文献类型:
--
作者:
Yoon, Jeong-Hwan;Jung, Su Myung;Park, Seok Hee;Kato, Mitsuyasu;Yamashita, Tadashi;Lee, In-Kyu;Sudo, Katsuko;Nakae, Susumu;Han, Jin Soo;Kim, Ok-Hee;Oh, Byung-Chul;Sumida, Takayuki;Kuroda, Masahiko;Ju, Ji-Hyeon;Jung, Kyeong Cheon;Park, Seong Hoe;Kim, Dae-Kee;Mamura, Mizuko

文献摘要

参考文献

相似文献

已经开发出多种转化生长因子-β (TGF-β) 拮抗剂来干预癌症中过度的 TGF-β 信号传导活性。激活素受体样激酶5 (ALK5) 抑制剂通过阻断 TGF-β 受体激活的 Smad (R-Smad) 磷酸化来拮抗 TGF-β 信号传导。在此,我们报告 ALK5 抑制剂如何对小鼠 B16 黑色素瘤模型发挥治疗作用的新机制。口服新型 ALK5 抑制剂 EW-7197(每日 2.5 毫克/公斤)或代表性 ALK5 抑制剂 LY-2157299(75 毫克/公斤,每日两次)可抑制黑色素瘤的进展,并增强细胞毒性 T 淋巴细胞 (CTL) 反应。值得注意的是,ALK5抑制剂不仅阻断R-Smad磷酸化,而且还诱导泛素介导的常见Smad、Smad4的降解,主要存在于黑色素瘤小鼠的CD8+T细胞中。因此,T 细胞特异性删除 Smad4 足以抑制黑色素瘤的进展。我们进一步确定了调节 CTL 功能的 T 盒转录因子 eomesodermin (Eomes),作为 CD8+ T 细胞中 TGF-β 通过 Smad4 和 Smad3 抑制的特定靶标。因此,除了对 R-Smad 磷酸化的直接抑制作用之外,ALK5 抑制还通过泛素介导的 Smad4 降解增强抗黑色素瘤 CTL 反应。
Varieties of transforming growth factor-β (TGF-β) antagonists have been developed to intervene with excessive TGF-β signalling activity in cancer. Activin receptor-like kinase5 (ALK5) inhibitors antagonize TGF-β signalling by blocking TGF-β receptor-activated Smad (R-Smad) phosphorylation. Here we report the novel mechanisms how ALK5 inhibitors exert a therapeutic effect on a mouse B16 melanoma model. Oral treatment with a novel ALK5 inhibitor, EW-7197 (2.5 mg/kg daily) or a representative ALK5 inhibitor, LY-2157299 (75 mg/kg bid) suppressed the progression of melanoma with enhanced cytotoxic T-lymphocyte (CTL) responses. Notably, ALK5 inhibitors not only blocked R-Smad phosphorylation, but also induced ubiquitin-mediated degradation of the common Smad, Smad4 mainly in CD8+ T cells in melanoma-bearing mice. Accordingly, T-cell-specific deletion of Smad4 was sufficient to suppress the progression of melanoma. We further identified eomesodermin (Eomes), the T-box transcription factor regulating CTL functions, as a specific target repressed by TGF-β via Smad4 and Smad3 in CD8+ T cells. Thus, ALK5 inhibition enhances anti-melanoma CTL responses through ubiquitin-mediated degradation of Smad4 in addition to the direct inhibitory effect on R-Smad phosphorylation.
DOI: 10.1038/ni1268
发表时间: 2005-12-01
期刊: NATURE IMMUNOLOGY
影响因子: 30.5
作者:
Intlekofer, AM;Takemoto, N;Reiner, SL
通讯作者: Reiner, SL
DOI: 10.1016/j.immuni.2011.01.017
发表时间: 2011-02-25
期刊: Immunity
影响因子: 32.4
作者:
Chang X;Liu F;Wang X;Lin A;Zhao H;Su B
通讯作者: Su B
DOI: 10.3109/03009734.2012.654858
发表时间: 2012-05
影响因子: 3.4
作者:
De Boeck M;ten Dijke P
通讯作者: ten Dijke P
DOI: 10.1182/blood-2010-08-298117
发表时间: 2011-01-06
期刊: BLOOD
影响因子: 20.3
作者:
Cho, Hyun-Il;Lee, Young-Ran;Celis, Esteban
通讯作者: Celis, Esteban
DOI: 10.1016/s1074-7613(01)00227-8
发表时间: 2001-11-01
期刊: IMMUNITY
影响因子: 32.4
作者:
Lee, PP;Fitzpatrick, DR;Wilson, CB
通讯作者: Wilson, CB